Internal Medicine, Hematology & Oncology · Scottsdale, AZ
NPI
1396723425
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
13400 E Shea Blvd
Scottsdale, AZ, 85259
Phone (480) 301-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
106,896 services
Medicare patients, 2024
820
Average age 75
Drug cost, 2024
$2.8M
494 prescriptions
Company payments, 2025
$208
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John K Camoriano was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 11,160 times for 48 patients. In total John K Camoriano billed 106,896 services in 153 codes, and Medicare paid $2.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 11,160 | 48 | $38.86 | $434K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,200 | 39 | $44.60 | $410K |
| J9299 Injection, nivolumab, 1 mg | Office | 7,900 | 16 | $23.02 | $182K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 7,350 | 44 | $0.11 | $813 |
| J9177 Injection, enfortumab vedotin-ejfv, 0.25 mg | Office | 6,160 | 14 | $28.45 | $175K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 5,385 | 13 | $2.32 | $12K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,344 | 22 | $0.08 | $356 |
| J9264 Injection, paclitaxel protein-bound particles, 1 mg | Office | 3,700 | 12 | $10.82 | $40K |
| J9025 Injection, azacitidine, 1 mg | Office | 3,260 | 13 | $0.31 | $1,002 |
| J0897 Injection, denosumab, 1 mg | Office | 2,340 | 23 | $20.54 | $48K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 1,170 | 18 | $34.99 | $41K |
| J9305 Injection, pemetrexed, not otherwise specified, 10 mg | Office | 1,110 | 12 | $3.10 | $3,442 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,064 | 93 | $0.09 | $96.67 |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 940 | 13 | $25.60 | $24K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 784 | 76 | $0.08 | $59.18 |
By year: 2022 $1.8M for 86,946 services; 2023 $1.7M for 92,121 services; 2024 $2.5M for 106,896 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 18 | 14 | $8.65 | $156 |
Medicare prescription drug claims, 2024
In 2024, the drug John K Camoriano prescribed most often to Medicare patients was Pegasys (Peginterferon Alfa-2a), with 97 prescriptions and refills. In total John K Camoriano wrote 494 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pegasys Peginterferon Alfa-2a | 97 | 99 | 14 | $397K |
| Hydroxyurea Generic | 93 | 216 | 22 | $2,278 |
| Jakafi Ruxolitinib Phosphate | 58 | 58 | Under 11 | $949K |
| Eliquis Apixaban | 44 | 68 | Under 11 | $41K |
| Promacta Eltrombopag Olamine | 24 | 24 | Under 11 | $463K |
| Inrebic Fedratinib Dihydrochloride | 17 | 17 | Under 11 | $313K |
| Nivestym Filgrastim-Aafi | 17 | 17 | Under 11 | $55K |
| Ojjaara Momelotinib Dihydrochloride | 13 | 13 | Under 11 | $363K |
| Abiraterone Acetate Generic | 12 | 12 | Under 11 | $27K |
Brand drugs: 297 claims; generic drugs: 197 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John K Camoriano $208 ($208 in general payments such as food, travel and fees) from 2 companies. The largest payer was Genzyme Corporation with $150.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 1 | $150 |
| Pinnacle Biologics, Inc | 1 | $58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.